MENU
BMGL
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

BMGL stock forecast, quote, news & analysis

Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
BMGL
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for BMGL with price predictions
Oct 21, 2026

Momentum Indicator for BMGL turns positive, indicating new upward trend

BMGL saw its Momentum Indicator move above the 0 level on October 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator turned positive. In 35 of the 40 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for BMGL just turned positive on October 09, 2026. Looking at past instances where BMGL's MACD turned positive, the stock continued to rise in 15 of 18 cases over the following month. The odds of a continued upward trend are 83%.

BMGL moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +9.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMGL advanced for three days, in 51 of 63 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMGL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for BMGL entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.118) is normal, around the industry mean (204.137). P/E Ratio (-0.648) is within average values for comparable stocks, (19.387). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.095) among similar stocks. P/S Ratio (0.597) is also within normal values, averaging (2.688).

The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. BMGL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMGL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 5.07B. The market cap for tickers in the group ranges from 20.9K to 99.46B. HCA holds the highest valuation in this group at 99.46B. The lowest valued company is NMMCF at 20.9K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was 1%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 22%. BMGL experienced the highest price growth at 15%, while NIVF experienced the biggest fall at -36%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was -62%. For the same stocks of the Industry, the average monthly volume growth was 11% and the average quarterly volume growth was -33%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 46
Price Growth Rating: 52
SMR Rating: 66
Profit Risk Rating: 86
Seasonality Score: -5 (-100 ... +100)